2023 Partners
Ginkgo Bioworks
Expertise Partner
Ginkgo Bioworks ($DNA) is the world’s leading horizontal platform for cell programming, providing flexible, end-to-end services solving challenges for biopharma companies, from discovery through manufacturing and across diverse therapeutic modalities. Leveraging cutting edge automation, large scale DNA synthesis, high throughput analytics, and machine learning, Ginkgo's platform enables partners to explore biological design space to discover and optimize their targets and processes, including end-to-end support for enzyme engineering projects to find the perfect design for our partners’ applications.
Basecamp Research
Expertise Partner
Basecamp Research is the world leader in mapping biodiversity for AI-based biological design. We match and refine novel proteins for our partners’ exact industrial, therapeutic or diagnostic applications using BaseGraph™, a new-generation of AI-design that is powered by the first ever high-resolution map of global genetic biodiversity. Understanding the full genetic, evolutionary and environmental context of each protein allows Basecamp Research to design process-ready enzymes for specific reactions without the need for expensive and time-consuming directed evolution campaigns. We’re a team of explorers, scientists and policy experts driven by our ambition to protect and learn from nature’s diversity, whilst delivering life-changing breakthroughs to those who need them most
For more information, visit www.basecamp-research.com, and follow us on X @Basecamp_Res and LinkedIn @basecamp-research.
Almac
Innovation Partner
Almac Sciences, an established, leading contract development and manufacturing organisation provides services for all stages of drug development for small molecules and peptides. Our expertise includes: API supply (preclinical to commercial manufacture); drug product development; stable and 14C radiolabelling; solid state services; biocatalysis, all of which are fully supported by a dedicated analytical team. Our biocatalysis team has expertise in enzyme engineering, enzyme supply, enzyme screening, developing new routes and manufacturing at scale, both GMP and non-GMP.
SEQENS
Innovation Partner
SEQENS, with more than 30 years-experience in the pharma industry, is the partner of choice in the Small Molecule Drug substance space. SEQENS proposes the highest level of service and commitment thanks to strong CMC project management team while acting ethically in accordance with a strong Environmental, Social and Governance program. SEQENS has State-of-the-art R&D facilities (in Europe and in the US) and an extensive network of 10 Western manufacturing sites (both GMP and non-GMP) permit SEQENS to offer the widest range of solutions to support the development of your new chemical entities. SEQENS support their customer from the very early stage of the development of their assets until commercial production:
• Preclinical R&D work (route scouting, non GMP tox batches…)
• Process and analytical development, QBD, kilo-lab and pilot production
• cGMP clinical supply
• non-GMP / GMP intermediates, RSMs and APIs manufacturing
• Standalone analytics (Nitrosamines quantification, solid state studies…)
• Pre-formulation work
Johnson Matthey
Hosting Partner
Johnson Matthey is a global leader in sustainable technologies. We apply our cutting-edge science to create solutions that make the world cleaner and healthier. As a technology-led organization, we share the pharmaceutical industry’s passion for R&D and innovation. Our expertise in catalysis, processing, and engineering has meant that JM technologies contributed to over 1 in 3 small molecule therapeutics approved by the US FDA in recent years. We work with customers through our market-leading range of catalysts to support the development and commercial manufacturing of advanced molecules.
bitBiome
Exhibition Partner
bitBiome is a platform company centered on their proprietary single cell microfluidic sequencing technology, (bit-MAP ®), which has enabled the creation of an extensive and distinctive microbial database of over 1.2 billion sequences, sourced primarily from environmental samples, containing sequences not present in public databases.
Leveraging their expertise in bioinformatics and machine learning, the company offers a comprehensive enzyme discovery and engineering platform, bit-QED. This encompasses the identification, assessment, and modification of enzymes through both in silico and wet lab evaluation, and directed evolution. The company excels in discovering novel microbial genes, pinpointing promising enzyme candidates, and refining them for industrial applications. They are committed to tackling global issues like plastic pollution and climate change through their offerings, aiming to contribute solutions to these challenges including those in the biocatalysis industries.
Sterling
Event Partner
Sterling Pharma Solutions is a global contract development and manufacturing organisation (CDMO) with 50+ years’ experience in providing small molecule API development and manufacturing services to the pharmaceutical industry, specialising in handling challenging chemistries.
Sterling manages the most complex API/intermediate challenges from proof-of-concept to commercial manufacture, as well as Antibody Drug Conjugate (ADC) development and manufacturing.
Sterling has five facilities employing 1,350+ people: its HQ in Cramlington, UK, a facility in Cork, Ireland; two sites in the US, in North Carolina and Wisconsin; and a dedicated bioconjugation and ADCs facility in Deeside, Wales.
Linkedin: /sterling-pharma-solutions
www.sterlingpharmasolutions.com
Codexis
Event Partner
Codexis is a leading enzyme engineering company leveraging its proprietary
CodeEvolver® platform to discover, develop and enhance novel, highperformance
enzymes. Codexis enzymes solve for challenges associated with
small molecule pharmaceuticals manufacturing and nucleic acid synthesis. Codexis is currently developing its proprietary ECO Synthesis™ platform to enable scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis’ enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, and improved efficiency in manufacturing.